Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
BIO Bio-Rad Laboratories
416.090
-4.010-0.95%
Post Mkt Price
416.0900.0000.00%
YOY
Do not show
Hide blank lines
(Q2)2022/06/30(Q1)2022/03/31(FY)2021/12/31(Q4)2021/12/31
Financial Ratios
Efficiency Ratios TTM
Cash Conversion Cycle(D)
4.23% 196.7526 -2.87% 187.8144 -13.60% 182.6359 -13.60% 182.6359
Receivable Turnover(T)
-10.81% 6.7582 -3.06% 6.6399 10.60% 6.934 10.60% 6.934
Inventory Turnover(T)
-3.63% 1.9632 1.90% 2.0687 13.95% 2.1463 13.95% 2.1463
Fixed Assets Turnover(T)
1.38% 4.3215 7.42% 4.2488 15.26% 4.2074 15.26% 4.2074
Total Asset Rate(T)
-9.58% 0.2065 -14.33% 0.2046 -21.66% 0.1901 -21.66% 0.1901
ROIC
-143.46% -17.710% -101.89% -0.874% -23.54% 35.275% -23.54% 35.275%
ROE
-144.34% -18.934% -102.01% -0.973% -25.93% 36.063% -25.93% 36.063%
ROA
-143.55% -13.974% -101.97% -0.714% -23.88% 27.617% -23.88% 27.617%
FCF to Sales
-37.79% 12.671% -19.12% 15.853% -2.05% 18.331% -2.05% 18.331%
FCF to Net Income
-- -- -- -- 0.81% 12.617% 0.81% 12.617%
Efficiency Ratios
ROE 5 Year Average
-- -- -- -- 34.70% 27.137% -- --
ROA 5 Year Average
-- -- -- -- 36.68% 20.026% -- --
Average 5 Years ROIC
-- -- -- -- 36.86% 25.372% -- --
Profitability Ratios TTM
Gross Margin
0.82% 57.053% 0.78% 56.758% -0.61% 56.138% -0.61% 56.138%
Operating Margin
3.64% 18.371% 13.42% 18.371% 3.74% 16.747% 3.74% 16.747%
Net Margin
-148.16% -67.657% -102.30% -3.492% -2.84% 145.281% -2.84% 145.281%
EBITDA Margin
-146.04% -0.8576% -101.57% -0.0317% -4.20% 1.9071% -4.20% 1.9071%
R & D Expense Ratio
0.77% 9.190% -3.33% 8.990% 4.49% 9.300% 4.49% 9.300%
Sales Expense Ratio
-- 0.000% -- 0.000% -- 0.000% -- 0.000%
Administration Expense Rate
-- 0.000% -- 0.000% -- 0.000% -- 0.000%
Financial Health Ratios
Long-Term Debt to Equity Ratio
908.16% 15.191% 694.30% 13.419% -28.10% 1.364% -28.10% 1.364%
Total Assets to Common Equity
9.01% 142.135% 7.48% 141.155% -0.94% 130.062% -0.94% 130.062%
Debt to Asset Ratio
752.95% 15.597% 564.25% 13.785% -28.47% 1.634% -28.47% 1.634%
Current Ratio
35.80% 5.2951 42.86% 5.0953 -13.79% 2.9211 -13.79% 2.9211
Quick Ratio
48.20% 3.9399 67.17% 3.914 -14.95% 1.8995 -14.95% 1.8995
GrowthRatios
Growth Ratios
Revenue CAGR(3Y)
-- -- -- -- 50.72% 8.479% -- --
Revenue CAGR(5Y)
-- -- -- -- 51.07% 7.161% -- --
Net Income CAGR(3Y)
-- -- -- -- -41.07% 126.455% -- --
Net Income CAGR(5Y)
-- -- -- -- 69.32% 172.757% -- --
FCF 1 Year Growth
-- -- -- -- -61.78% 12.449% -- --
FCF CAGR(3Y)
-- -- -- -- -- 50.978% -- --
FCF CAGR(5Y)
-- -- -- -- 5.80% 48.230% -- --
Currency Unit
USDUSDUSDUSD

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
Bio-Rad Laboratories, Inc. engages in the development and production of specialty chemicals used in biochemical, pharmaceutical, and other life science research applications. It operates through the Life Sciences and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets reagents, apparatus, and laboratory instruments. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, and test kits. The company was founded by David S. Schwartz and Alice N. Schwartz in 1952 and is headquartered in Hercules, CA.
CEO: Mr. Norman Schwartz
Market: NYSE
Listing Date: 10/24/2008
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist